(Health Korea News / Changyong Lee) Samchundang Pharmaceutical announced on the 14th that it recorded sales of 52.3 billion won in the third quarter through its quarterly report. This is an 8.13% increase compared to the same period last year (KRW 48.4 billion).
However, operating profit in the third quarter was -800 million won, turning into a loss from the same period last year (2.3 billion won).
Net profit for the third quarter was -284 million won. Although the deficit was maintained compared to the same period last year (-10.3 billion won), the deficit improved significantly.
Cumulative sales in the first to third quarters amounted to KRW 155.7 billion, an increase of 11.09% compared to the same period last year (KRW 140.1 billion). Cumulative operating profit and accumulated net profit were KRW 3.1 billion and KRW 3.8 billion, respectively, down 57.37% and 62.2% compared to the same period last year.
(Samcheongdang Pharmaceutical’s consolidated operating performance for the third quarter of 2024)
|
division(unit: million won%) |
Current performance |
previous year performance |
Rate of change compared to the previous quarter |
Performance for the same period last year |
Rate of change compared to the same period last year |
|
|
(24year 3branch) |
(24year 2branch) |
(23year 3branch) |
||||
|
take |
Current performance |
52,382 |
54,889 |
|
48,442 |
8.13% |
|
Cumulative performance |
155,729 |
– |
– |
140,177 |
11.09% |
|
|
operating profit |
Current performance |
-814 |
2,137 |
|
2,383 |
deficit conversion |
|
Cumulative performance |
3,186 |
– |
– |
7,474 |
-57.37 |
|
|
net profit |
Current performance |
-284 |
1,826 |
|
-10,339 |
Continuing deficit |
|
Cumulative performance |
3,863 |
– |
– |
11,102 |
-65.2% |
|
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited
Source: www.hkn24.com
